Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026
Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026
Company Deals

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026
Company Deals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Fineline Cube Aug 12, 2026
Company Deals

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Fineline Cube Aug 12, 2026
Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Fineline Cube Aug 12, 2026
Company Deals

Lee’s Pharmaceutical Secures Rights to Eyedetec’s Dry Eye Device in Asia-Pacific

Fineline Cube Jun 9, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622)...

Company Drug

NMPA Approves Betta Pharmaceuticals’ Vorolanib for Second-Line RCC Treatment in Combination with Everolimus

Fineline Cube Jun 9, 2023

The National Medical Products Administration (NMPA) has granted approval for Betta Pharmaceuticals Co., Ltd’s (SHE:...

Company Drug

Zelgen Biopharmaceuticals’ ZGGS15 Earns FDA Approval for Advanced Solid Tumor Clinical Trial

Fineline Cube Jun 9, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Drug

CSPC Pharmaceutical’s CPO301 Receives Health Canada Approval for Phase I Study

Fineline Cube Jun 9, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...

Company Deals R&D

Shanghai Fosun High Technology Partners with NICE for Joint Innovation Centers

Fineline Cube Jun 9, 2023

China-based conglomerate Shanghai Fosun High Technology (Group) Co., Ltd has entered into a partnership with...

Company Deals

Samyang Holdings Partners with Yxintent for Lafullen Dermal Filler in China

Fineline Cube Jun 9, 2023

South Korea-based Samyang Holdings Biopharm Group has secured a partnership with Hangzhou-based Yxintent, a specialist...

Deals

Sequoia Capital to Split into Three Units, Including Independent China and India/SEA Divisions

Fineline Cube Jun 8, 2023

US-based investment fund Sequoia Capital has declared plans to reorganize its business into three distinct...

Company Drug

Jacobio Pharma Gets Green Light for Phase I/IIa Study of PARP7 Inhibitor JAB-26766

Fineline Cube Jun 8, 2023

China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to initiate a Phase...

Company

BioMarin Pharmaceutical to Discontinue Vimizim Import License in China

Fineline Cube Jun 8, 2023

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced its decision not to renew the Import Drug...

Company Drug

Vcanbio Receives NMPA Approval for VUM02 Stem Cell Therapy in Liver Failure and ARDS

Fineline Cube Jun 8, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...

Company Drug

Dizal Pharmaceutical Presents Updates on Sunvozertinib and Golidocitinib at ASCO 2023

Fineline Cube Jun 8, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...

Company Drug

Abbisko Therapeutics’ Pimicotinib Earns PRIME Status for TGCT from EMA

Fineline Cube Jun 8, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that its Category 1 drug...

Company Medical Device

NMPA Approves Shenzhen Core Medical’s Implantable Left Ventricular Assist System

Fineline Cube Jun 8, 2023

The National Medical Products Administration (NMPA) has issued market approval for the implantable left ventricular...

Company Deals

uBriGene Partners with Everlife Biomed to Advance iPSC Therapy Preparation

Fineline Cube Jun 8, 2023

China-based uBriGene, a leading cell and gene therapy contract development and manufacturing organization (CDMO), has...

Company

EpimAb Biotherapeutics Appoints Dr. Zhu Yonghong as Chief Medical Officer

Fineline Cube Jun 8, 2023

Shanghai-based biotech company EpimAb Biotherapeutics has announced the appointment of Dr. Zhu Yonghong to the...

Company Drug

CStone Pharmaceuticals and Servier Report Positive AGILE Study Results for Tibsovo at ASCO

Fineline Cube Jun 7, 2023

CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has published the latest results of the global...

Company Drug

BioNTech’s DB-1303 ADC Shows Promising Results in Solid Tumor Phase I/IIa Trial

Fineline Cube Jun 7, 2023

Germany’s BioNTech (NASDAQ: BNTX) has released preliminary data from a Phase I/IIa trial for DB-1303,...

Company Drug

Gilead’s Kite Announces Breakthrough Phase III Results for Yescarta in r/r LBCL

Fineline Cube Jun 7, 2023

Gilead’s (NASDAQ: GILD) subsidiary Kite has published groundbreaking Phase III results for Yescarta (axicabtagene ciloleucel),...

Company Drug

ITabMed Ltd Receives NMPA IND Approval for A-337, a CD3-Activating BsAb Targeting EpCAM

Fineline Cube Jun 7, 2023

Shanghai-based biotech firm ITabMed Ltd has announced the receipt of Investigational New Drug (IND) approval...

Policy / Regulatory

China’s MOST Issues Updated HGR Rules Impacting Foreign Collaborations in Genetic Research

Fineline Cube Jun 7, 2023

China’s Ministry of Science and Technology (MOST) has issued the “Detailed Implementation Rules for the...

Posts pagination

1 … 558 559 560 … 707

Recent updates

  • Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal
  • NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib
  • Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million
  • Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026
  • Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal

Company Medical Device

NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.